Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 8/2018

01-06-2018 | Adis Drug Evaluation

Mirabegron: A Review in Overactive Bladder Syndrome

Author: Emma D. Deeks

Published in: Drugs | Issue 8/2018

Login to get access

Abstract

The first-in-class β3-adrenoceptor agonist mirabegron is indicated in the EU (Betmiga™), Japan (Betanis™) and several other countries for the management of overactive bladder (OAB) syndrome. Evidence for its use in this setting includes several large phase 3 trials. Compared with placebo, oral mirabegron for 12 weeks reduced the frequency of micturition and generally also that of incontinence, with other benefits including reduced urgency, increased void volume and improved health related quality-of-life (HR-QOL). Mirabegron comparisons versus tolterodine are descriptive; however, in a 12-week powered comparison versus solifenacin in patients dissatisfied with antimuscarinic efficacy, mirabegron did not demonstrate noninferiority in reducing micturition frequency or significantly differ in terms of improving other urinary symptoms. Urinary and HR-QOL benefits of mirabegron were sustained over up to 52 weeks of treatment and the drug was generally well tolerated, with a numerically lower incidence of dry mouth than antimuscarinics. Real-world data support the trial findings and indicate possible persistence and adherence benefits for mirabegron over antimuscarinics. Mirabegron use is not generally restricted by patient age, sex or antimuscarinic treatment status, although data in men (from a phase 4 study and phase 3 trial subanalyses) are variable; additional studies in older and male OAB patients are awaited with interest. Although further longer-term efficacy and tolerability data would be beneficial, current clinical evidence indicates that mirabegron provides an alternative to antimuscarinics for the management of OAB in adults, including those for whom antimuscarinics have proven unsuitable.
Literature
1.
Gormley EA, Lightner DJ, Faraday M, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015;193(5):1572–80.CrossRefPubMed
2.
3.
Thiagamoorthy G, Cardozo L, Robinson D. Current and future pharmacotherapy for treating overactive bladder. Expert Opin Pharmacother. 2016;17(10):1317–25.CrossRefPubMed
4.
Palmer CJ, Choi JM. Pathophysiology of overactive bladder: current understanding. Curr Bladder Dysfunct Rep. 2017;12:74–9.CrossRef
5.
6.
Wagg A, Nitti VW, Kelleher C, et al. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics. Curr Med Res Opin. 2016;32(4):621–38.CrossRefPubMed
7.
8.
Astellas Pharma Inc. Betanis tablet: Japanese prescribing information. Tokyo: Astellas Pharma Inc.; 2015.
9.
Takasu T, Ukai M, Sato S, et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4’-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective β3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther. 2007;321(2):642–7.CrossRefPubMed
10.
11.
12.
Nitti VW, Rosenberg S, Mitcheson DH, et al. Urodynamics and safety of the β3-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol. 2013;190(4):1320–7.CrossRefPubMed
13.
Matsukawa Y, Takai S, Funahashi Y, et al. Urodynamic evaluation of the efficacy of mirabegron on storage and voiding functions in women with overactive bladder. Urology. 2015;85(4):786–90.CrossRefPubMed
14.
Sawada N, Nomiya M, Hood B, et al. Protective effect of a β3-adrenoceptor agonist on bladder function in a rat model of chronic bladder ischemia. Eur Urol. 2013;64(4):664–71.CrossRefPubMed
15.
Sacco E, Bientinesi R, Tienforti D, et al. Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence. Exp Opin Drug Discov. 2014;9(4):433–48.CrossRef
16.
Alexandre EC, Kiguti LR, Calmasini FB, et al. Mirabegron relaxes urethral smooth muscle by a dual mechanism involving β3-adrenoceptor activation and α1-adrenoceptor blockade. Br J Pharmacol. 2016;173(3):415–28.CrossRefPubMedPubMedCentral
17.
Malik M, van Gelderen EM, Lee JH, et al. Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study. Clin Pharmacol Ther. 2012;92(6):696–706.CrossRefPubMed
18.
Mo W, Michel M, Kaumann A, et al. Cardiostimulant effects of mirabegron in human atrium and ventricle in vitro [abstract no. 571]. Heart Lung Circ. 2017;26(Suppl 2):S291.CrossRef
19.
van Gelderen M, Stolzel M, Meijer J, et al. An exploratory study in healthy male subjects of the mechanism of mirabegron-induced cardiovascular effects. J Clin Pharmacol. 2017;57(12):1534–44.CrossRefPubMed
20.
Nitti VW, Chapple CR, Walters C, et al. Safety and tolerability of the β3-adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised phase III trials and of a 1-year randomised phase III trial. Int J Clin Pract. 2014;68(8):972–85.CrossRefPubMed
21.
Batista JE, Kolbl H, Herschorn S, et al. The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial. Ther Adv Urol. 2015;7(4):167–79.CrossRefPubMedPubMedCentral
22.
Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β3-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63(2):296–305.CrossRefPubMed
23.
Novack GD, Lewis RA, Vogel R, et al. Randomized, double-masked, placebo-controlled study to assess the ocular safety of mirabegron in healthy volunteers. J Ocul Pharmacol Ther. 2013;29(7):674–80.CrossRefPubMed
24.
Iitsuka H, Tokuno T, Amada Y, et al. Pharmacokinetics of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder, in healthy Japanese male subjects: results from single- and multiple-dose studies. Clin Drug Investig. 2014;34(1):27–35.CrossRefPubMed
25.
Eltink C, Lee J, Schaddelee M, et al. Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder. Int J Clin Pharmacol Ther. 2012;50(11):838–50.CrossRefPubMed
26.
Krauwinkel W, van Dijk J, Schaddelee M, et al. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women. Clin Ther. 2012;34(10):2144–60.CrossRefPubMed
27.
Iitsuka H, van Gelderen M, Katashima M, et al. Pharmacokinetics of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder, in healthy East Asian subjects. Clin Ther. 2015;37(5):1031–44.CrossRefPubMed
28.
Lee J, Zhang W, Moy S, et al. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults. Clin Ther. 2013;35(3):333–41.CrossRefPubMed
29.
Takusagawa S, van Lier JJ, Suzuki K, et al. Absorption, metabolism and excretion of [14C]mirabegron (YM178), a potent and selective β3-adrenoceptor agonist, after oral administration to healthy male volunteers. Drug Metab Dispos. 2012;40(4):815–24.CrossRefPubMed
30.
Konishi K, Tenmizu D, Takusagawa S. Identification of uridine 5′-diphosphate-glucuronosyltransferases responsible for the glucuronidation of mirabegron, a potent and selective β3-adrenoceptor agonist, in human liver microsomes. Eur J Drug Metab Pharmacokinet. 2017. https://​doi.​org/​10.​1007/​s13318-017-0450-x.CrossRef
31.
Lee J, Moy S, Meijer J, et al. Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist. Clin Drug Investig. 2013;33(6):429–40.CrossRefPubMed
32.
Dickinson J, Lewand M, Sawamoto T, et al. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron. Clin Drug Investig. 2013;33(1):11–23.CrossRefPubMed
33.
Yamaguchi O, Ikeda Y, Ohkawa S. Phase III study to assess long-term (52-week) safety and efficacy of mirabegron, a β3-adrenoceptor agonist, in Japanese patients with overactive bladder. Low Urin Tract Symptoms. 2017;9(1):38–45.CrossRefPubMed
34.
Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63(2):283–95.CrossRefPubMed
35.
Herschorn S, Barkin J, Castro-Diaz D, et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β3 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013;82(2):313–20.CrossRefPubMed
36.
Kuo HC, Lee KS, Na Y, et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourol Urodyn. 2015;34(7):685–92.CrossRefPubMed
37.
Nitti VW, Auerbach S, Martin N, et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013;189(4):1388–95.CrossRefPubMed
38.
Yamaguchi O, Marui E, Kakizaki H, et al. Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder. BJU Int. 2014;113(6):951–60.CrossRefPubMed
39.
Kim HW, Shin DG, Yoon SJ, et al. Mirabegron as a treatment for overactive bladder symptoms in men: efficacy and safety results from a multicenter, randomized, double-blind, placebo-controlled, parallel comparison phase IV study (MIRACLE study) [abstract no. 273]. Neurourol Urodyn. 2017;36(Suppl. 3):S247–9.
40.
Nitti VW, Khullar V, van Kerrebroeck P, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract. 2013;67(7):619–32.CrossRefPubMedPubMedCentral
41.
Chapple CR, Nitti VW, Khullar V, et al. Onset of action of the β3-adrenoceptor agonist, mirabegron, in phase II and III clinical trials in patients with overactive bladder. World J Urol. 2014;32(6):1565–72.CrossRefPubMedPubMedCentral
42.
Chapple C, Khullar V, Nitti VW, et al. Efficacy of the β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomised phase 3 trials. Eur Urol. 2015;67(1):11–4.CrossRefPubMed
43.
Khullar V, Amarenco G, Angulo JC, et al. Patient-reported outcomes with the β3-adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder. Neurourol Urodyn. 2016;35(8):987–94.CrossRefPubMed
44.
Castro-Diaz D, Chapple CR, Hakimi Z, et al. The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized phase III trials. Qual Life Res. 2015;24(7):1719–27.CrossRefPubMedPubMedCentral
45.
Khullar V, Cambronero J, Angulo JC, et al. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian phase 3 trial. BMC Urol. 2013;13(45):1–9.
46.
Wagg A, Cardozo L, Nitti VW, et al. The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients. Age Ageing. 2014;43(5):666–75.CrossRefPubMed
47.
Tubaro A, Batista JE, Nitti VW, et al. Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies. Ther Adv Urol. 2017;9(6):137–54.CrossRefPubMedPubMedCentral
48.
49.
50.
51.
Kato D, Uno S, Van Schyndle J, et al. Persistence and adherence to overactive bladder medications in Japan: a large nationwide real-world analysis. Int J Urol. 2017;24(10):757–64.CrossRefPubMed
52.
Wagg A, Franks B, Ramos B, et al. Persistence and adherence with the new β3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: early experience in Canada. Can Urol Assoc J. 2015;9(9–10):343–50.CrossRefPubMedPubMedCentral
53.
54.
Chapple CR, Nazir J, Hakimi Z, et al. Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice. Eur Urol. 2017;72(3):389–99.CrossRefPubMed
55.
56.
57.
58.
59.
Benner JS, Nichol MB, Rovner ES, et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010;105(9):1276–82.CrossRefPubMed
60.
Sharaf AA, Hashim H. Profile of mirabegron in the treatment of overactive bladder: place in therapy. Drug Des Dev Ther. 2017;11:463–7.CrossRef
61.
62.
63.
Andersson KE, Sarawate C, Kahler KH, et al. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder. BJU Int. 2010;106(2):268–74.CrossRefPubMed
64.
Rosa GM, Ferrero S, Nitti VW, et al. Cardiovascular safety of β3-adrenoceptor agonists for the treatment of patients with overactive bladder syndrome. Eur Urol. 2016;69(2):311–23.CrossRefPubMed
65.
Chapple CR, Siddiqui E. Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia. Expert Rev Clin Pharmacol. 2017;10(2):131–51.CrossRefPubMed
66.
67.
Simeone JC, Nordstrom BL, Appenteng K, et al. Replication of Mini-Sentinel study assessing mirabegron and cardiovascular risk in non-Mini-Sentinel databases. Drugs Real World Outcomes. 2018;5(1):25–34.CrossRefPubMed
68.
Kakizaki H, Lee KS, Yamamoto O, et al. Efficacy and safety of add-on mirabegron vs. placebo to tamsulosin in men with overactive bladder symptoms (MATCH study) [abstract no. LBA13]. J Urol. 2018;199(4S Suppl.):e988.CrossRef
69.
Maman K, Aballea S, Nazir J, et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol. 2014;65(4):755–65.CrossRefPubMed
70.
71.
National Institute for Health and Care Excellence. Mirabegron for treating symptoms of overactive bladder. Technology appraisal guidance. 2013. http://​www.​nice.​org.​uk. Accessed 18 May 2018.
72.
Nazir J, Berling M, McCrea C, et al. Economic impact of mirabegron versus antimuscarinics for the treatment of overactive bladder in the UK. Pharmacoecon Open. 2017;1(1):25–36.CrossRefPubMedPubMedCentral
73.
Nazir J, Maman K, Neine ME, et al. Cost-effectiveness of mirabegron compared with antimuscarinic agents for the treatment of adults with overactive bladder in the United Kingdom. Value Health. 2015;18(6):783–90.CrossRefPubMed
74.
Aballea S, Maman K, Thokagevistk K, et al. Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom. Clin Drug Investig. 2015;35(2):83–93.CrossRefPubMed
75.
Angulo JC, Sanchez-Ballester F, Peral C, et al. Cost effectiveness analysis of fesoterodine compared to mirabegron in first-line therapy setting for overactive bladder with urge urinary incontinence, from the Spanish National Health System perspective. Actas Urol Esp. 2016;40(8):513–22.CrossRefPubMed
Metadata
Title
Mirabegron: A Review in Overactive Bladder Syndrome
Author
Emma D. Deeks
Publication date
01-06-2018
Publisher
Springer International Publishing
Published in
Drugs / Issue 8/2018
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-018-0924-4

Other articles of this Issue 8/2018

Drugs 8/2018 Go to the issue

Correction

Correction to: Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension

Current Opinion

Colorectal Cancer: Why Does Side Matter?

AdisInsight Report

Tildrakizumab: First Global Approval

Review Article

Management of Embolic Stroke of Undetermined Source (ESUS)

Letter to the Editor

Authors’ Reply to Pires et al.: “Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes”

Leading Article

Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review